Exhilarating Times: Innovation, Development, and Change

In this discussion, John Quilter, Chief Executive Officer of Saanroo®, describes the company’s strategic separation of its pharmaceutical and nutraceutical operations to give each business focused leadership and resources. The nutraceutical arm now operates globally as Saanroo®, a name the team says is inspired by the Tamil word for “evidence,” and reflects a renewed emphasis on clinically validated ingredients. Quilter underscores the company’s long-term commitment to clinical science—pointing to more than 50 completed clinical studies and numerous trials still underway as the proof points that will guide future product development.

Ramasamy Venkatesh, Managing Director of Gencor Pacific, highlights the expanding evidence base for Levagen®+, the company’s PEA formulation delivered with an optimized absorption system. He discusses recent work presented from a University of Westminster trial that used validated cognitive measures and found a 21% improvement in memory, along with increases in BDNF and meaningful reductions in stress markers for female participants as measured by heart-rate variability. Venkatesh frames these findings as part of a broader research program—roughly 15 published studies with additional ongoing work—positioning Levagen®+ for applications across cognition, stress resilience, and women’s health.

Gulhan Demirci, Chief Innovation Officer at Pharmako Biotechnologies Pty Lyd, presents two new launches that leverage advanced delivery technology. BioBerp® is a liposomal/dispersion-enabled berberine formulation (LipoS-style technology) that achieves substantially improved bioavailability, allowing efficacious outcomes at a reduced 300 mg dose and markedly lower gastrointestinal side effects compared with traditional berberine products. Trpti® is a protected, bioavailable form of the endogenous fatty acid OEA designed to survive digestive degradation and act at the intestinal target site; clinical work discussed includes microbiome studies, increases in GLP-1, reductions in intestinal inflammation, immune marker improvements, and weight reductions in cohorts selected for gut dysbiosis. Demirci also notes acute GLP-1 responses and DPP-4 downregulation observed in studies—mechanisms that together suggest Trpti® can support satiety, fat metabolism, and metabolic health in a physiologically complementary way.